(Q24247723)

2

0 references

Stephanie K Li

3

0 references

Cintia Curioni

4

0 references

David CW Lau

Cochrane Database of Systematic Reviews

5

0 references

publication date

20 October 2003

0 references

published in

0 references

cites work

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Effect of orlistat on cardiovascular disease risk in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Orlistat for obesity: benefits beyond weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Pharmacologic induction of weight loss to treat type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Two-year outcome of a combination of weight loss therapies for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Randomized trial of lifestyle modification and pharmacotherapy for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Reduction of body weight and co-morbidities by orlistat: The XXL--Primary Health Care Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Long-term effects of change in body weight on all-cause mortality. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

The efficacy and safety of sibutramine for weight loss: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Medicinal strategies in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Weight gain as a risk factor for clinical diabetes mellitus in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Rimonabant for overweight or obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Impact of overweight on the risk of developing common chronic diseases during a 10-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Prevalence and Trends in Obesity Among US Adults, 1999-2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Prospective study of intentionality of weight loss and mortality in older women: the Iowa Women's Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Assessing the Quality of Randomised Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Obesity and the risk of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Regional adiposity and morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Obesity as a medical problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Changes in energy expenditure resulting from altered body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Body Weight and Mortality among Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

A systematic review of drug therapy to delay or prevent type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

A prospective study of body mass index, weight change, and risk of stroke in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Investigating and Dealing with Publication and Other Biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

The effect of age on the association between body-mass index and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

The association between weight loss and increased longevity. A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

Orlistat in the long-term treatment of obesity in primary care settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

Prevalence and trends in overweight among US children and adolescents, 1999-2000

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

Towards prevention of obesity: research directions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

Obesity: a time bomb to be defused

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

1 reference

7 January 2021

Weight loss increases and fat loss decreases all-cause mortality rate: results from two independent cohort studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

A comparison of body mass index, waist-hip ratio and waist circumference as predictors of all-cause mortality among the elderly: the Rotterdam study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

Treatment with orlistat reduces cardiovascular risk in obese patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

1 reference

7 January 2021

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021

The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004094.PUB2

7 January 2021